A recent study from the Gastrointestinal Stem Cell Biology Laboratory, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK; Translational Gastroenterology Unit, Experimental Medicine Division,, shows that “Aberrant epithelial GREM1 expression initiates colonic tumorigenesis from cells outside the stem cell niche.” This study was published in the 1 December 2014 issue of the Journal “Nature Medicine” [the number 1 journal in General medicine with an impact factor of 24.973] by Prof. Leedham SJ and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Anticancer stem cell therapy: Gremlin-1 (GREM1) increases the expression of oncomiR miRNA-17-92 via down regulation of its target gene. This study suggests, for the first time, Gremlin-1, by decreasing the expression of its target gene BMP4, it may : (1) increase the expression of miRNA-17-92; (2) decrease the expression of a number of tumor suppressor genes; and (3) promote cancer stem cell prolifertion and selfrenewal. Thus, pharmacological formulations encompassing “Gremlin-1 inhibitors” may be used to inhibit cancer stem cell proliferation and self-renewal.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Anticancer stem cell therapy: Gremlin-1 (GREM1) increases the expression of oncomiR miRNA-17-92 via down regulation of its target gene, 7/May/2015, 23.01, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
Undisclosed information: How Gremlin-1 increases the expression of oncomiR miRNA-17-92
